Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Amy Crowe et al.|JAMA|2018Cited by 761
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>Mario Tumbarello, Pierluigi Viale, Enrico Maria Trecarichi et al.|Clinical Infectious Diseases|2018Cited by 351
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysisElda Righi, David L. Paterson, Anna Maria Peri et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 114
Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohortElisa Gentilotti, Cinzia Perlini, Anna Górska et al.|EClinicalMedicine|2023Cited by 103